The Omicron BA.1 variant–specific vaccine NVX-CoV2515 elicited a superior neutralizing antibody response against the Omicron BA.1 subvariant as compared with the prototype vaccine, NVX-CoV2373, when administered as a fourth dose. Safety data were consistent with the established safety profile of NVX-CoV2373.
All Keywords
【저자키워드】 neutralizing antibody, SARS-CoV-2, reactogenicity, Omicron BA.1, NVX-CoV2373,
【저자키워드】 neutralizing antibody, SARS-CoV-2, reactogenicity, Omicron BA.1, NVX-CoV2373,